Instem Plc had a “super” first half, according to chief executive Phil Reason who joined Proactive Investors’ Stocktube to discuss six months boosted by new deals and continued organic growth.
The company today unveiled positive results, for the six months ending June 30, including revenues that had risen by more than a fifth.
Performance was boosted by a new US standard for of clinical data requirements. SEND - or Standard for the Exchange of Non-clinical Data – comes in to force this December and Instem picked up six contracts specifically for the new protocol in the half year to June.
Reason highlighted that there are hundreds if not thousands of submissions each year that will need to be compliant with the SEND rules.
“Instem is by far the leading supplier to answer those concerns,” Reason added.
Instem boss Phil Reason hails super first half and talks new business and growth
Published: 11:51 19 Sep 2016 BST